Hengrui's 2020 financial report: revenue of 27.7 billion oncology drugs contributes 55% and PD-1 triples!

On April 19, Hengrui announced its 2020 annual report.

Hengrui Medicine's revenue, net profit and R&D investment in the past 10 years (unit: 100 million yuan)

Hengrui Medicine's R&D investment growth trend in the past 10 years

Hengrui Pharmaceutical's main business involves drug R&D, production and sales, and its main products cover many fields such as anti-tumor drugs.

Among Hengrui's revenue of RMB 100 million in 2020, oncology drugs contributed 15.

Performance of Hengrui's major product business segments (100 million yuan)

R&D expenses increased by 28%, innovative drugs and generic drugs go hand in hand

Up to now, Hengrui's innovative drugs are irecoxib, apatinib mesylate, thiopefigrastim, pirotinib maleate, carrelizumab, remazolam tosylate and fluorophore Zopali is launched.

Investment in Hengrui's main R&D projects (unit: ten thousand yuan)

Basic situation of Hengrui's main R&D projects

The status of Hengrui's products submitted to regulatory authorities for approval during the reporting period

In terms of consistency evaluation, Hengrui has 9 products passed the consistency evaluation in 2020.

Hengrui passed the consistency evaluation of the number of varieties and the bidding situation of centralized procurement

A number of innovative drugs have started international multi-center phase III clinical trials

In terms of internationalization, Hengrui will continue to increase the implementation of its internationalization strategy in 2020 and actively expand overseas markets.

In terms of the internationalization of generic drugs, dexmedetomidine hydrochloride and sodium chloride injection was approved for sale in the United States.

In terms of the internationalization of innovative drugs, a number of products have been approved to conduct global multi-center or regional clinical studies.